Adicet Bio, Inc. 8K

Adicet Bio furnished an investor presentation describing development timelines, clinical plans, and milestone expectations for prula-cel in autoimmune disease, ADI-212 in mCRPC, and its in vivo CAR-T oncology pipeline.

Adicet Bio furnished a September 2026 Investor Overview presentation outlining its clinical and regulatory development plans and timelines for its lead allogeneic CAR-T candidate prula-cel in autoimmune diseases (including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis), its next-generation gene-edited, armored γδ1 CAR-T candidate ADI-212 for metastatic castrate-resistant prostate cancer, and a preclinical in vivo CAR-T pipeline for multiple myeloma, non-Hodgkin lymphoma, and solid tumors, including anticipated IND clearances, trial initiations, key data readouts from 2026–2029, and related forward-looking financial and operational expectations such as cash runway assumptions.

Filing Facts

CIK

1720580

Ticker

-

Form

8K

Source Type

sec

Accession

0001720580-26-000056

Alert Tier

5